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first evidence of cisplatin-induced induction of the Akt/PKBRole and regulation of activation of caspases in cisplatin-induced
phosphorylation pathway, inhibition of which enhances activa-injury to renal tubular epithelial cells.
tion of caspase-3 and caspase-9.Background. Cellular and molecular mechanisms responsi-
ble for cisplatin-induced nephrotoxicity to renal tubular epithe-
lial cells are not well understood. Although caspases play a crit-
ical role in the execution of the cell death pathway, their specific The chemotherapeutic drug cisplatin, commonly usedrole in toxic injury to renal tubular epithelial cells has not been
for the treatment of solid tumors of a wide range of tis-elucidated previously.
sues [1–3], is generally associated with nephrotoxicity asMethods. The role of caspases in cisplatin-induced injury
was determined using caspase inhibitors and p35 transfected one of its major side effects. The primary targets of cis-
LLC-PK1 cells. The Akt/PKB phosphorylation pathway was platin in kidney are the proximal tubular epithelial cells
studied for the regulation of caspase activation in these cells. where it accumulates and promotes the damage of theseResults. The activation of initiator caspases-8, -9 and -2, and
cells [3, 4]. The cellular and molecular mechanisms re-executioner caspase-3 began after eight hours of cisplatin treat-
sponsible for drug-induced nephrotoxicity to renal tubu-ment, thereafter markedly increased in a time (8 to 24 hours)
and dose-dependent manner (0 to 200 mol/L). Proinflamma- lar epithelial cells are not well understood. Although casp-
tory caspase-1 did not show cisplatin-induced activation. Inhibi- ases play a critical role in the execution of the cell death
tion of caspase-3 by over expressing cowpox virus p35 protein pathway, their specific role in toxic injury to renal tubularor alternatively by the peptide inhibitor DEVD-CHO provided
epithelial cells has not been elucidated previously.marked protection against cell death and partial protection
Caspases (originally known as interleukin 1-convert-against DNA damage. We then examined the role of the Akt/
PKB phosphorylation pathway in regulation of cisplatin-induced ing enzyme and its family of proteases) are a family of
caspase activation. There was a marked induction of Akt/PKB cell death proteases [5] that plays an essential role in the
phosphorylation in a time (0 to 8 hours) and dose-dependent execution phase of apoptosis [6–11]. Thus far, 14 mem-(0 to 200 mol/L) manner during the course of cisplatin injury.
bers of the caspase family have been identified fromCisplatin-induced Akt/PKB activation was associated with Bad
mammalian cells [11, 12]. Caspase-8, -9, -10, and -2 havephosphorylation, suggesting induction of a cell survival signal
mediated by the Bcl-2 family member, Bad. Wortmannin or large prodomains and initiate the activation of down-
LY294002, two structurally dissimilar inhibitors of phosphati- stream caspases, and caspase-3, -6, and -7 with smaller do-
dylinositol 3-kinase (PI-3 kinase), abolished both cisplatin- mains are identified as executioner caspases [11]. Theinduced Akt phosphorylation and Bad phosphorylation, and
downstream executioner caspase-3 is responsible for thepromoted cisplatin-induced early and accelerated activation of
cleavage of a wide variety of physiological substratescaspase-3 and caspase-9, but not of caspase-8 and caspase-
1, indicating that inhibition of the Akt/PKB phosphorylation including DNA repair enzymes [13, 14], ICAD (inhibitor
pathway enhances the mitochondrial-dependent activation of of caspase-activated DNase) or DNA fragmentation fac-
caspases. The impact of enhanced activation of caspases by tor [15, 16], nuclear structural proteins [11, 17], and cyto-wortmannin or LY294002 was reflected on accelerated cis-
skeleton proteins [11, 18, 19]. At present, there are twoplatin-induced cell death.
relatively well-characterized cell death pathways that re-Conclusions. These studies demonstrate differential activa-
tion and role of caspases in cisplatin injury, and provide the sult in the activation of downstream or executioner cas-
pases. One is receptor-mediated and the other is mito-
chondrial-dependent. The receptor-dependent pathwayKey words: nephrotoxicity, acute renal failure, cisplatin, kidney, kidney
injury, Akt/PKB phosphorylation pathway. is initiated by activation of cell death receptors (Fas and
tumor necrosis factor) that activates procaspase-8, whichReceived for publication May 2, 2001
in turn cleaves and activates downstream caspases-3and in revised form June 20, 2001
Accepted for publication June 22, 2001 [20–22]. The mitochondrial-dependent pathway is trig-
gered by cytochrome c release from the mitochondria 2001 by the International Society of Nephrology
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that promotes the activation of procaspase-9 through pase inhibitors, DEVD-CHO, IETD-CHO, and LEHD-
CHO were purchased from Bachem Inc. (Torrance, CA,Apaf-1 and dATP. Activated caspase-9 then cleaves and
activates the downstream pro-caspase-3 [23–25]. How- USA) and ZVAD-FMK was from Enzyme Systems prod-
ucts (Dublin, CA, USA). Caspase substrates were pur-ever, whether cisplatin-induced activation of caspases
are involved with these signaling pathways is not known. chased from Peptide International (Louisville, KY,
USA) and antibodies to caspases were from Santa CruzCurrently, there is limited information on the role
of caspases in cisplatin-induced renal tubular epithelial Biotechnology (Santa Cruz, CA, USA). Anti-Akt, anti-
ser-473-phosphorylated Akt, anti-Bad, anti-ser-136 phos-(RTE) cell injury. Cisplatin has been shown to induce cell
death in renal tubular epithelial cells [26–30]. Caspase-3 phorylated Bad, anti-ser-112 phosphorylated Bad anti-
bodies were obtained from Cell Signaling Technologyis activated in renal proximal tubular cells [31, 32] by
cisplatin treatment, suggesting that cisplatin-induced cell (Beverly, MA, USA). Expression plasmid for p35 and
antibody to p35 were kindly provided by Dr. Anu Srini-death is mediated by caspases. We have previously dem-
onstrated that renal tubular epithelial cells transcribe vasan, Idun Pharmaceuticals (La Jolla, CA, USA).
and express multiple caspases, including the initiator and
Treatment with cisplatinexecutioner caspases [33]. However, there is no informa-
tion on the specific role and regulation of the underlying Cells were replaced with fresh DMEM containing se-
rum, glutamine, pyruvate, nonessential amino acids, glu-mechanism(s) of signaling pathways responsible for the
activation of caspases in cisplatin-induced cellular injury. cose, 3.7 g/L NaHCO3 and 20 mmol/L HEPES at pH 7.4
and incubated either with or without cisplatin of variousCells have inherited information to initiate the apo-
ptotic pathway in response to a death stimuli unless they concentrations for the period of time indicated. In initial
studies, we determined the optimum exposure time andare challenged by cell survival signals that maintain cell
viability. On receiving a death stimulus, both cell death the suitable concentration of cisplatin. To determine a
role of caspases in cisplatin-induced cell death, cells wereand cell survival pathways can be induced during the
course of cellular injury. Therefore, the extent of cellular preincubated with caspase inhibitors, DEVD-CHO for
caspase-3 and LEHD-CHO for caspase-9 for 30 minutes,injury caused by a toxic agent will depend on the balance
between activation of caspases triggered by toxic injury washed, and exposed to cisplatin (50 mol/L).
and on the induction of survival factors capable of block-
Determination of caspase activitying the activation of caspases. At present, there is no in-
formation on the induction of survival signals that regu- Cells were harvested by centrifugation and the pellets
were washed in cold phosphate-buffered saline (PBS)late caspase activation during cisplatin-induced cellular
injury. The present study provides evidence that cisplatin twice. The washed cell pellets were lysed with 20 mmol/L
HEPES, pH 7.5, containing 10% sucrose, 0.1% CHAPS-not only triggers selective and differential activation of
caspases but also causes induction of the PI3/Akt path- 3 - [(3 - cholamidopropyl)dimethylamino-1]propane -sul-
fonate), 2 mmol/L dithiothreitol (DTT), 0.1% NP40,way of cell survival, a signaling pathway previously unrec-
ognized in cisplatin-induced cellular injury. The studies 1 mmol/L ethylenediaminetetraacetic acid (EDTA), 1
mmol/L phenylmethylsulfonyl fluoride (PMSF), 1g/mLalso demonstrate the specific role of executioner cas-
pase-3 and enhanced activation of this caspase and the leupeptin, and 1 g/mL pepstatin A at 4C. The superna-
tants obtained after centrifugation were used to deter-initiator caspase, caspase-9, by inhibition of the PI-3 kinase/
Akt phosphorylation pathway during cisplatin-induced mine the enzyme activity. The activities of caspase-1,
-2, -3, -8, and -9 were determined by fluorometric as-injury to renal tubular epithelial cells.
say using the substrates; YVAD-AMC for caspase-1,
VDVAD-AMC for caspase-2, DEVD-AMC for caspase-
METHODS
3, LEHD-AMC for caspase-9, and IETD-AMC for cas-
Cell culture and reagents pase-9, which are specifically cleaved by the respective
enzymes at the Asp residue to release the fluorescentLLC-PK1 cells obtained from American Type Culture
Collection (Rockville, MD, USA) were cultured as in our leaving group, amino-4-methyl coumarin (AMC) [35,
36]. The enzyme extracts containing 50 g protein wereprevious studies [34]. The cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with incubated with 100 mmol/L HEPES, pH 7.4, containing
10% sucrose, 0.1% CHAPS, 10 mmol/L DTT, and 5010% heat-inactivated fetal calf serum, 2 mmol/L l-gluta-
mine, 20 mmol/L 4-(2-hydroxy ethyl)-1-piperazine ethane- mol/L of caspase substrate in a total reaction volume
of 0.25 mL. The reaction mixture was incubated for 60sulfonic acid (HEPES), and 2 mmol/L nonessential amino
acids. Cultures were maintained in a humidified incuba- minutes at 30C. At the end of incubation, the liberated
fluorescent group AMC was determined using a fluores-tor gassed with 5% CO2 and 95% air at 37C and fed with
fresh medium at intervals of 48 to 72 hours. Experiments cent Spectrofluorometer (Perkin Elmer) with an excita-
tion wavelength of 380 nm and an emission wavelengthwere performed with cells grown to 80% confluence. Cas-
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of 460 nm [36]. AMC was used as a standard. Based on containing 10% isopropanol and destained in the same
solvent without Coomassie blue.the standard curve made with fluorescence reading with
free AMC, the data for caspase activity are expressed
Western blot analysisas nmol of AMC liberated when 50 g of protein extract
was incubated with 50mol/L of substrate for 60 minutes The cell lysates were prepared as described previously
in this article for caspase assay and 100 g protein sam-at 30C.
ples were subjected to reducing SDS-gel electrophoresis.
Determination of DNA damage The resolved proteins were electrophoretically transferred
to Immobilon polyvinylidine difluoride (Millipore, Bed-The residual double-stranded DNA was measured by
the alkaline unwinding assay and determination of ethid- ford, MA, USA) membrane and processed further for
antibody staining as described by Towbin, Staehelin andium bromide fluorescence according to the method of
Birnboim and Jevcak [37], as utilized in our previous stud- Gordon [40]. Following this transfer, the membranes
were washed in a buffer containing 50 mmol/L Tris-HCl,ies [38, 39]. Ethidium bromide fluorescence was mea-
sured at 520 nm excitation and 590 nm emission using pH 7.5, 150 mmol/L NaCl, and 0.05% Tween 20 for five
minutes, and then in the same buffer containing 5% non-a fluorescence spectrophotometer. Under the conditions
employed, ethidium bromide binds preferentially to dou- fat dry milk for an hour at room temperature. The mem-
branes were then incubated for five hours with antibodiesble-stranded DNA. Percent double-strand DNA (D) was
determined by the equation: %D 100 [F(P) F(B)]/ to caspases (usually 1:1000 dilution) in the same buffer
with 5% dry milk as described previously in this article.[F(T)  F(B)], where F(P) is the sample fluorescence,
F(T) is the total fluorescence prior to alkaline treatment, The incubations were done at room temperature on a plat-
form shaker to ensure thorough mixing. At the end of thisand F(B) is the background fluorescence that was ob-
tained from sonicated, alkaline-treated DNA, a condi- time, the membranes were thoroughly washed (at least
4 times) with 50 mmol/L Tris-HCl, pH 7.5, containingtion under which the DNA is completely unwound and
represents the fluorescence due to all components other 0.05% Tween 20. The membrane filters were then incu-
bated for two hours with horseradish peroxidase-conju-than double-stranded DNA.
gated goat anti-rabbit antibody diluted 1:3000 in Tris buf-
Detection of DNA fragmentation by agarose fer containing 5% dry milk. After incubation, membrane
gel electrophoresis filters were washed in the same buffer (50 mmol/L Tris-
HCl and 150 mmol/L NaCl only) containing 0.05% TweenTo assess DNA fragmentation, fragmented DNA was
isolated from LLC-PK1 cells as previously described 20 and developed by exposure to chemiluminescent sub-
strates (Pierce, Rockford, IL, USA).[38, 39]. Cells were collected by centrifugation at 200 g
for 10 minutes, and the pellets were lysed with 1.0 mL
Overexpression of p35of lysis buffer containing 0.5% Triton X-100, 10 mmol/L
Tris-HCl, pH 8.0, 25 mmol/L EDTA for one to two hours LLC-PK1 cells were transfected with expression plas-
mid pcDNA-3 containing the p35 full-length cDNA. p35at 4C. The lysates were centrifuged at 16,000  g for
20 minutes to separate the fragmented DNA (superna- viral protein has been reported to be an effective inhibi-
tor of caspase-3 [41–43]. Transfection was performed us-tant) from the intact DNA (pellet). The resulting super-
natant containing fragmented DNA was incubated with ing Lipofectamine (Life Technologies, Grand Island, NY,
USA) as per the manufacturer’s recommendation. In brief,proteinase K (200 g/mL) at 50C overnight. The DNA
was extracted with phenol-chloroform-isoamyl alcohol cells were plated at a density of 2 105 in six-well plates.
After 24 hours, cells were washed thrice with serum-free(50:49:1), followed by precipitation with 0.1 volumes of
3 mol/L sodium acetate and 2.5 volumes of 100% etha- media and incubated for five hours with a mixture of
Lipofectamine and plasmids containing the inserts (1.5Lnol. The samples were suspended in 10 mmol/L Tris-HCl,
pH 7.5, containing 0.5 mmol/L EDTA. The concentra- of Lipofectamine, 50 L of serum-free medium and 1 g
of DNA in 50 L of serum-free medium) in serum-freetion of nucleic acid in each sample was determined by
ultraviolet absorbance at 260 nm. The fragmented DNA media at 37C with 10% CO2. Cells were then grown in
the presence of G418 and selected for G418-resistantisolated from each sample was treated with RNAse
(20 g/mL) at 37C for three hours and subjected to clones. After cell recovery, cells were examined for the
expression of p35 A by Western blot using p35 antibody.electrophoresis on a 1% agarose gel. After electrophore-
sis, the DNA was visualized by ultraviolet fluorescence The transfected cells were also examined for the suppres-
sion of caspase-3 activity using the fluorogenic substrateafter staining with ethidium bromide.
Sodium dodecyl sulfate (SDS) polyacrylamide gel elec- DEVD-AMC. These cells were then used to examine the
protection against cisplatin-induced injury. After variabletrophoresis (PAGE) was performed as previously de-
scribed [33] using 8% polyacrylamide gels. The gels were periods of cisplatin treatment, DNA damage and cell death
were determined in the over-expressing cells as describedstained with 0.05% Coomassie blue in 10% acetic acid
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Fig. 1. Time course effect of cisplatin on activation of caspases. LLC-
Fig. 2. Effect of caspase inhibitors on cisplatin–induced caspase activa-PK1 cells were exposed to 50 mol/L of cisplatin at various times as
tion. Cells were treated with 50 mol/L of cisplatin for 20 hours in theshown. To determine the caspase activity, cell lysates (50 g protein)
presence and absence of caspase inhibitors (50 mol/L): DEVD-CHOwere incubated with fluorogenic peptide substrates at 37C for 60 min-
for caspase-3, IETD-CHO for caspase-8, and LEHD-CHO for caspase-utes as described in the Methods section. The production of liberated
9. The caspase activity in cell lysates (50 g protein) was determinedfluorescent amino-4-methyl coumarin (AMC) was determined with an
as described in the Methods section. Results are mean  SE, N  4.excitation wavelength of 380 nm and an emission wavelength of 460
*P 	 0.001 compared with cisplatin-treated controls.nm using a spectrofluorometer (Perkin Elmer). AMC was used as a
standard. The data for caspase activity are expressed as nmol of AMC
liberated when 50 g of protein extract was incubated with 50 mol/L
of substrate for 60 minutes at 30C. Values are means  SE (N  5).
Symbols from top to bottom curves are: () DEVD-MCA, caspase-3; caspase-2, respectively, also were increased but to lesser() VDVAD-MCA, caspase-2; () LEHD-MCA, caspase-9; ()
degree than caspase-3 (Fig. 1). However, the activity ofIETD-MCA, caspase-8; () YVAD, caspase-1.
proinflammatory caspase-1 [11] was not detected in cis-
platin-treated cells, indicating that cisplatin does not acti-
vate proinflammatory caspase-1. The substrate specificity
in our studies [34] and compared to control cells to exam- of the caspases may be promiscuous, but was overcome
ine the effect of the inhibitor in this model of injury. by identifying the activation by Western blot analysis (dis-
cussed later in this article) using specific antibodies to
Statistical analyses
each caspase. The cisplatin-induced activation of caspases
Results are mean  SE. Comparison between values was suppressed by peptide inhibitors of caspases (Fig. 2).
was determined by the Student t test. A P value of less Caspases are synthesized as inactive proenzymes and
than 0.05 was considered significant. in response to an apopoptotic stimuli are activated by
proteolytic processing of the proenzyme. In the process
of activation the inactive proenzyme is proteolyticallyRESULTS
cleaved to the smaller subunits of about 20 and 10 kD
Role of caspases in cisplatin-induced injury in size [11]. In response to an injury, the identity of the
To elucidate the role of caspases in cisplatin-induced active form of the caspase produced can be revealed by
injury to LLC-PK1 cells, we first examined the activity Western blot analysis using a specific antibody to the
of the initiator caspases, caspase-9, -8, -2, and the execu- caspase. Thus, to examine the exact identity and activa-
tioner caspase, caspase-3 in response to cisplatin injury to tion of initiator and executioner caspases during cis-
LLC-PK1 cells. The activity of caspases was determined platin-induced injury to LLC-PK1 cells, we performed
using fluorometric peptide substrates specific for each of Western blot analysis using specific antibodies to cas-
the caspases. As shown in Figure 1, the activity of DEVD- pase-3, -8, and -9. As shown in Figure 3, proteolytic
AMC cleavage began at approximately eight hours of processing of procaspase-3 results in the formation of a
cisplatin treatment and then significantly increased with 17 kD subunit of the active caspase-3. This activation
increasing periods of cisplatin (50 mol/L) treatment, began at eight hours of cisplatin (50 mol/L) treatment
suggesting the activation of caspase-3. The maximal acti- and thereafter progressively increased up to 24 hours of
vation occurred at 24 hours of cisplatin treatment. The the treatment. Caspase-8 was also proteolytically pro-
activities of cleavage of IETD-AMC, LEHD-AMC, and cessed as shown by the gradual decrease in the band of
its proform (the antibody to caspase-8 used was specificVDVAD-AMC substrates for caspase-8, caspase-9, and
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Fig. 3. Time course expression and activation of caspases in response
to cisplatin. Cells were treated with 50 mol/L cisplatin for various
time periods as indicated. Cell lysates (100 g protein) were subjected
to Western blot analyses using antibodies specific for caspase-3,
caspase-8, and caspase-9, respectively.
to the proform only and did not recognize the processed
subunits; Fig. 3). Similarly, caspase-9 was proteolytically
processed to result in a 37 kD (prodomain 
 large frag-
ment) and a 17 kD subunit of the active form. Moreover,
Fig. 4. (A) Protection of cisplatin-induced cell death in caspase inhibitor,caspase-9 protein expression apparently was increased p35 transfected LLC-PK1 cells. p35 transfected cells () and control trans-
upon cisplatin treatment. The proteolytic processing of fected cells () were exposed to various concentrations of cisplatin for
20 hours. Following incubations, cell death was determined by trypan bluecaspase-3, -8, and -9 to their active forms was in agree-
exclusion. Results are mean  SE, N  4. *P 	 0.002 compared with
ment with the increased activities of these caspases, as control transfected cells. (B) Effect of peptide inhibitors of caspases
on cisplatin-induced cell death. Cells were exposed to 25 mol/L andshown in Figure 1. The activation of caspase-8 and -9
50 mol/L cisplatin with and without the caspase-3 inhibitor, DEVD-should precede caspase-3 according to the known path- CHO (), and the caspase-9 inhibitor, LEHD-CHO ( ), for 20 hours
ways of receptor-mediated or mitochondrial-dependent as indicated. Cell death was determined by trypan blue exclusion. Results
are mean  SE, N  4. *P 	 0.002 compared with the controls ().activation of caspase-8 and -9, respectively. The data
presented in Figures 1 and 3 show that activation of
caspase-3 may precede that of caspase-8 and -9, sug-
gesting that this activation of caspase-3 may be contrib- 3, P 	 0.002) and as determined by DNA fragmentation
uted by an unknown pathway or other caspases. pattern on agarose–gel electrophoresis (Fig. 5).
Since cowpox viral protein is a potent inhibitor of cas-
pase-3 [41–43], we developed a stably transfected LLC- Induction of cisplatin-induced PI-3 kinase/
PK1 cell line that overexpressed the p35 caspase inhibi- Akt phosphorylation and its effect on
tor. The transfected cells provided marked protection caspase activation and cell death
against cisplatin-induced cell death (Fig. 4A). Peptide The serine/threonine kinase Akt is one of the down-
inhibitors of caspase-3 and caspase-9 also provided sig- stream targets of phosphatidylinositol 3-kinase (PI-3 ki-
nificant protection against cisplatin-induced cell death in nase) [44, 45] and PI-3 kinase-dependent Akt phosphory-
LLC-PK1 cells (Fig. 4B). However, inhibition of caspases lation provides an important mechanism for resistance
provided partial protection against cisplatin-induced to cell death in response to injury [44, 46]. Phosphoryla-
DNA damage as measured by DNA unwinding assay tion of Akt leads to full activation of Akt that can result
(residual double-stranded DNA in control cells, 95  in phosphorylation of its direct downstream target, Bad,
3%; 50 mol/L cisplatin, 46 2%; 50 mol/L cisplatin
 a member of the Bcl-2 family [47–49]. When phosphory-
lated, Bad dissociates from Bcl-XL or Bcl-2 [50] and re-25 mol/L DEVD-CHO, 72  3%; p35, 77  2%; N 
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not changed during the course of cisplatin injury. Since
activated Akt can phosphorylate Bad, we examined the
time course of Bad phosphoryation in cisplatin-induced
injury. As shown in Figure 7, Bad phosphorylation was
markedly increased at least up to eight hours of cisplatin
treatment and then declined in longer periods. These
studies indicate that Bad phosphorylation is associated
with Akt phosphorylation during cisplatin-induced in-
jury and may be involved in the suppression of caspase
activation in early time periods (at least up to 8 hours)
of cisplatin treatment. Indeed, phosphorylation of both
Akt and Bad were abolished in a dose-dependent man-
ner by LY294002 (0 to 10mol/L; Fig. 8) or by wortman-
nin (0 to 0.25 mol/L; data not shown), inhibitors of PI-3
kinase. Since Akt phosphorylation is known to block
apoptosis and promote cell survival [44, 46], the inhibi-
tion of Akt phosphorylation should potentiate enhanced
caspase activation during the course of cisplatin injury.
As shown in Figure 9, wortmannin (0.25 mol/L) resulted
in an early and enhanced increase in cisplatin-induced casp-
ase-3 and caspase-9 activation compared with the activa-
tion by cisplatin alone in a time- (0 to 24 hours; Fig. 9A)
and dose-dependent (0 to 100 mol/L of cisplatin for 12
hours) manner (Fig. 9B). Wortmannin (0.25mol/L) alone
(as shown in Fig. 9B at zero cisplatin concentration) slightly
increased caspase-3 and caspase-9 activation, but this acti-
vation was far less compared to the activation by cisplatin
alone or by wortmannin and cisplatin together. Thus, these
studies indicate that inhibition of Akt phosphorylation
enhance mitochondrial-dependent caspase-9 and caspase-3
activation in cisplatin-induced injury. In marked contrast,
inhibition of Akt phosphorylation did not affect the cis-
platin-induced caspase-8 and proinflammatory caspase-1
activities (Fig. 10). Thus, the receptor-mediated pathway
that activates procaspase-8 and proinflammatory casp-
ase-1 are not affected by inhibition of Akt phosphoryla-
tion in cisplatin-induced injury. These studies indicate thatFig. 5. Effect of caspase inhibition on cisplatin–induced DNA fragmen-
Akt phosphorylation regulates the mitochondrial-depen-tation. Lanes are: C; control, CP (50 mol/L); cells were exposed to
50 mol/L cisplatin for 20 hours. CP (50 mol/L)
I (25 mol/L); cells dent caspase-9 and caspase-3 activation in cisplatin-induced
were exposed to 50 mol/L cisplatin and 25 mol/L of DEVD-CHO injury. We next examined the effect of LY294002 on thefor 20 hours. CP (50 mol/L) 
 p35; p35 transfected cells exposed to
cisplatin-induced proteolytic processing of caspase-3 and50 mol/L cisplatin for 20 hours. The fragmented DNA was isolated
from each sample as described in the Methods section and subjected caspase-9 from their proforms to the active forms. This
to 1% agarose gel electrophoresis and visualized with ethidium bromide. was done by Western blot analysis using specific anti-
bodies to caspase-3 and caspase-9. As shown in Figure 11,
LY294002 (5 mol/L) resulted in the appearance of
active caspase-3 and caspase-9 as early as two hours ofstores their antiapoptotic function by preventing caspase-9
activation and, subsequently, caspase-3 activation [51–53]. cisplatin treatment and enhanced activation of these
caspases in later time points. These data suggest thatThus, we first examined cisplatin-induced Akt phosphor-
ylation and consequential Bad phosphorylation, and then inhibition of the PI-3 kinase/Akt pathway not only re-
sults in earlier activation of caspase-3 and -9 but alsothe downstream effects of this phosphorylation on sup-
pression of caspase activation. Western blot analysis using at higher levels in cisplatin-induced injury to renal tubu-
lar epithelial cells. The inhibition of cisplatin-inducedanti-phospho Akt antibody revealed a marked increase
in cisplatin-induced Akt phosphorylation in a time- and Akt phosphorylation was also reflected in early and en-
hanced cell death (Fig. 12). Figure 12 shows that cis-dose-dependent manner (Fig. 6). However, the protein
expression of Akt as determined using Akt antibody was platin-induced cell death is markedly enhanced by inhibi-
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Fig. 6. Time course and dose-dependent acti-
vation of Akt in response to cisplatin. (A) Cells
were treated with 50 mol/L cisplatin for vari-
ous time periods as indicated. Cell lysates (100
g protein) were analyzed for Akt activation
by Western blot analyses using specific anti-
bodies to phosphorylated Akt (ser-473) and
Akt, respectively. (B) Cells were treated with
various concentrations of cisplatin for 20 hours
as indicated. Cell lysates (100g protein) were
analyzed for Akt activation by Western blot
analyses using specific antibodies to phosphor-
ylated Akt and Akt, respectively.
Fig. 7. Time course of Bad phosphorylation in response to cisplatin.
Cells were treated with 50 mol/L cisplatin for various time periods as
indicated. Cell lysates (100g protein) were analyzed for Bad phosphor-
ylation by Western blot analyses using specific antibodies to phosphory-
lated Bad (ser-136) and Bad, respectively.
tion of Akt phosphorylation. These studies indicate that
enhanced activation of caspase-3 and caspase-9 by inhibi-
tion of Akt phosphorylation also has an impact on cis-
Fig. 8. (A) Dose-dependent inhibition of Akt phosphorylation by PI-3platin-induced cell death. kinase inhibitor, LY294002. Cells were treated with 50 mol/L cisplatin
in the presence or absence of various concentrations (0 to 10 mol/L)
of LY294002 (LY) for four hours as indicated. Cell lysates were analyzed
DISCUSSION for Akt activation by Western blot analysis using antibodies to phos-
phorylated Akt (ser-473) and Akt. (B) Dose-dependent inhibition ofThe executioner caspase-3 recently has been shown
Bad phosphorylation by PI-3 kinase inhibitor, LY294002. Cells were
to be activated by cisplatin treatment in renal proximal treated with 50 mol/L cisplatin in the presence or absence of various
concentrations (0 to 10mol/L) of LY294002 for four hours. Cell lysatestubular cells [30, 31]. However, there is no information
were analyzed for Bad phosphorylation by Western blot analysis usingon the specific role and underlying mechanism(s) of sig-
specific antibodies to phosphorylated Bad (ser-136) and Bad alone.
naling pathways responsible for the regulation of down-
stream caspase-3 and other upstream caspases that may
be activated during cisplatin-induced injury to renal tu-
bular epithelial cells. Our data indicate that cisplatin activation of these caspases was markedly inhibited by
their respective peptide inhibitors, suggesting that theseinduces selective and differential activation of caspases
including executioner caspase-3 and initiator caspase-8 caspases may play an important role in cisplatin-induced
injury to renal tubular epithelial cells. DEVD-CHO orand -9, but not proinflammatory caspase-1. The selective
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Fig. 9. (A) Time course effect of wortmannin
on cisplatin-induced caspase-3 and caspase-9
activation. Cells were treated with 50 mol/L
cisplatin in the presence () or absence ()
of wortmannin (0.25 mol/L) for various time
periods as indicated. The caspase activity in cell
lysates (50 g protein) was determined using
substrates DEVD-AMC for caspase-3 and
LEHD-AMC for caspase-9. The incubations
were as described in Methods section. Results
are mean  SE, N  4. *P 	 0.005 compared
with cisplatin treated cells. (B) Dose-depen-
dent effect of cisplatin (0 to 100 mol/L) in
presence and absence of wortmannin (0.25
mol/L) on activation of caspase-3 and cas-
pase-9. Cells were treated with treated with 0
to 100 mol/L cisplatin as indicated in the
presence () or absence () of wortmannin
(0.25 mol/L) for 12 hours. The caspase activ-
ity in cell lysates (50 g protein) was deter-
mined using substrates DEVD-AMC for cas-
pase-3 and LEHD-AMC for caspase-9. The
incubations were as described in the Methods
section. Results are mean  SE, N  4. *P 	
0.01 compared to cisplatin-treated cells.
Fig. 10. Effect of wortmannin on cisplatin-
induced caspase-8 and caspase-1 activation.
Cells were treated with 50 mol/L cisplatin in
the presence () or absence () of wortman-
nin (5 mol/L) for various time periods as
indicated. The caspase activity in cell lysates
(50 g protein) was determined using sub-
strates IETD-AMC for caspase-8 and YVAD-
AMC for caspase-1. The incubations were as
described in the Methods section. Results are
mean  SE, N  5. *P 	 0.002 compared
with cisplatin-treated cells.
LEHD-CHO, inhibitors of caspase-3 and caspase-9, re- cating that Akt phosphorylation is dependent on the acti-
vation of PI-3 kinase. Akt (also known as protein kinase B)spectively, provided marked protection against cisplatin-
induced cell death and partial protection against DNA was originally identified as the cellular homolog of the
transforming oncogene of the AKT8 retrovirus [58, 59].damage in LLC-PK1 cells as revealed by an alkaline
unwinding assay and by agarose gel electrophoresis. The Recent studies from several laboratories have recognized
PI-3 kinase/Akt phosphorylation as one of the signalingspecific role of caspase-3 and its more direct involvement
in cisplatin-induced injury came from studies utilizing pathways that blocks apoptosis and promotes cell sur-
vival in response to diverse apoptotic stimuli in differentthe baculovirus protein p35, which is a potent inhibitor
of caspase-3 [42–44]. Over-expression of p35 blocks the cell types [44–47, 60, 61]. However, the role of Akt phos-
phorylation in determining the cell fate in cisplatin-induction of apoptosis in insect and mammalian cells
[54–56]. Thus, a stably transfected LLC-PK1 cell line de- induced injury is not known. Several pathways have been
proposed for PI-3/Akt phosphorylation-mediated cellveloped to over-express p35 was capable of providing pro-
tection against cisplatin-induced injury indicating that cis- survival [44]. One of the well-studied molecules that
mediates cell survival by Akt phosphorylation is the pro-platin injury involves the participation of caspases.
Our studies also show that cisplatin induces the phos- apoptotic Bcl-2 family member Bad. Bad has the ability
to directly interact and bind to antiapoptotic Bcl-2 andphorylation of the antiapoptotic serine/threonine kinase
Akt and that this phosphorylation is inhibited by PI-3 Bcl-XL and blocks their survival function [50, 54, 61, 62].
Phosphorylated Akt can directly phosphorylate Bad bothkinase inhibitors LY294002 and wortmannin [57], indi-
Kaushal et al: Caspases in toxic acute renal failure1734
Fig. 12. Effect of wortmannin on cisplatin–induced time course of cell
death. Cells were treated with 50 mol/L of cisplatin in the presence ()
or absence () of wortmannin for the time points indicated. Following
incubations, cell death was determined by trypan blue exclusion. Results
are mean  SE, N  5. *P 	 0.001 compared with control cisplatin-
treated cells.
Fig. 11. Effect of LY294002 on cisplatin-induced time course expres-
sion and activation of caspase-3 and caspase-9. Cells were treated with
50 mol/L cisplatin in the presence of LY294002 (5 mol/L) for various that inhibition of PI-3 kinase/Akt phosphorylation trig-
time periods as indicated. Cell lysates (100 g protein) were subjected gers early activation of caspase-3 and caspase-9 and en-to Western blot analyses using antibodies specific for caspase-3 and
hanced cell death, indicating the possibility that activa-caspase-9.
tion of Akt modulates the response to cisplatin injury.
The apoptotic pathway is a highly regulated process
and cells have inherited information to initiate this path-
in vitro and in vivo [47, 48, 61], and may render Bad way in response to a death stimulus. Once initiated by an
incapable of binding to Bcl-XL and restore the antiapo- apoptotic stimulus, the cell death pathway can be chal-
ptotic function of Bcl-2 [44, 62]. Sequestering phosphory- lenged by cell survival signals to overcome injury and main-
lated Bad by 14-3-3 proteins [50, 61] also may participate tain cell viability. Thus, the extent of cell injury caused by
in the Akt survival pathway by making it unavailable to a toxic agent will depend on the balance between activa-
bind to Bcl-2 or prevent it from damaging the mitochon- tion of caspases triggered by a toxic agent and on the
dria. Many studies have provided evidence that Bcl-2 induction of survival signals capable of blocking the ac-
family members regulate activation of caspases through tivation of caspases. The data presented in this article
control of cytochrome c release from the mitochondria clearly demonstrate that cisplatin not only triggers cas-
[51, 62] and by directly binding to Apaf 1, thus preventing pase activation, but also causes induction of the PI-3
the activation of procaspase-9 and subsequently caspase-3 kinase/Akt pathway and impacts on cell survival. These
[53]. Our study presents evidence that PI-3 kinase-medi- observations have not been previously recognized in re-
ated Akt phosphorylation is associated with Bad phos- nal tubular epithelial cell injury. Our studies thus provide
phorylation and suppression of caspase-9 and caspase-3 new targets to modulate cisplatin-induced injury to renal
activation. Indeed, our studies show that wortmannin tubular epithelial cells. It is possible that enhancing the
and LY294002, inhibitors of PI-3 kinase block cisplatin- renal-specific cell survival signals and inhibiting death
induced phosphorylation of both Akt and Bad and en- signals will lead to preservation of renal function in toxic
hance activation of caspase-9 and caspase-3 by cisplatin. injury.
On the other hand, these inhibitors had no effect on the
activation of proinflammatory caspase-1 and receptor- ACKNOWLEDGMENTS
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